Carsten Brunn, PhD, president and chief executive officer of Selecta Biosciences, joins CGTL to discuss ImmTOR, an immune tolerance platform that could ultimately enable gene therapy redosing in certain cases.
"This study has quite broad implications. It's the first time anyone has shown in a human healthy volunteer study that we can inhibit the formation of antibodies, which, down the line, might enable redosing." — Carsten Brunn, PhD, president and chief executive officer of Selecta Biosciences
The prime concern in gene therapy development, of course, is safety, and one of the limitations of adeno-associated virus (AAV) gene therapy is that it is traditionally thought of as "one and done," in that one dose is highly immunogenic.
But what if a "low and slow" approach was possible and enabled potentially safe and efficacious redosing?
That is the idea behind Selecta Biosciences' ImmTORTM platform, which seeks to mitigate unwanted immune responses that can interfere with the activity of biologic therapies.
Joining CGTL is Carsten Brunn, PhD, president and chief executive officer of Selecta Biosciences, to discuss ImmTORTM, as well as the company's clinical programs, including SEL-302 for methylmalonic acidemia (MMA).